244 related articles for article (PubMed ID: 30680823)
1. Fumaric acid ester-induced T-cell lymphopenia in the real-life treatment of psoriasis.
Dickel H; Bruckner T; Höxtermann S; Dickel B; Trinder E; Altmeyer P
J Eur Acad Dermatol Venereol; 2019 May; 33(5):893-905. PubMed ID: 30680823
[TBL] [Abstract][Full Text] [Related]
2. Lymphopenia and CD4+/CD8+ Cell Reduction under Fumaric Acid Esters.
Sondermann W; Rompoti N; Leister L; Huptas L; Klode J; Dissemond J; Körber A
Dermatology; 2017; 233(4):295-302. PubMed ID: 28954274
[TBL] [Abstract][Full Text] [Related]
3. Long-term real-life safety profile and effectiveness of fumaric acid esters in psoriasis patients: a single-centre, retrospective, observational study.
Dickel H; Bruckner T; Altmeyer P
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1710-1727. PubMed ID: 29705996
[TBL] [Abstract][Full Text] [Related]
4. A case series of persistent lymphopaenia following treatment with fumaric acid esters for psoriasis.
Beatty PE; Killion L; Callaghan G; Tierney E; Kelly G; Tobin AM
J Clin Pharm Ther; 2021 Jun; 46(3):859-861. PubMed ID: 33432649
[TBL] [Abstract][Full Text] [Related]
5. The Implications of Recent Recommendations for Managing Patients with Psoriasis Treated with Fumaric Acid Esters.
Foley CC; Molloy OE; Lally A; Kirby B
Dermatology; 2017; 233(2-3):175-177. PubMed ID: 28869956
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis.
Hoefnagel JJ; Thio HB; Willemze R; Bouwes Bavinck JN
Br J Dermatol; 2003 Aug; 149(2):363-9. PubMed ID: 12932244
[TBL] [Abstract][Full Text] [Related]
7. Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study.
Wain EM; Darling MI; Pleass RD; Barker JN; Smith CH
Br J Dermatol; 2010 Feb; 162(2):427-34. PubMed ID: 19519838
[TBL] [Abstract][Full Text] [Related]
8. Fumaric acid esters for psoriasis: a systematic review.
Smith D
Ir J Med Sci; 2017 Feb; 186(1):161-177. PubMed ID: 27271164
[TBL] [Abstract][Full Text] [Related]
9. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities.
Balasubramaniam P; Stevenson O; Berth-Jones J
Br J Dermatol; 2004 Apr; 150(4):741-6. PubMed ID: 15099371
[TBL] [Abstract][Full Text] [Related]
10. Fumaric acid esters in the management of severe psoriasis.
Brewer L; Rogers S
Clin Exp Dermatol; 2007 May; 32(3):246-9. PubMed ID: 17362235
[TBL] [Abstract][Full Text] [Related]
11. Lymphopenia and fumaric acid esters for psoriasis: a retrospective case series prompted by the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) recommendations.
Roche L; Lynch M; Ahmad K; Hackett C; Ramsay B
Clin Exp Dermatol; 2018 Jan; 43(1):72-75. PubMed ID: 29027699
[No Abstract] [Full Text] [Related]
12. Proteinuria with fumaric acid ester treatment for psoriasis.
Ogilvie S; Lewis Jones S; Dawe R; Foerster J
Clin Exp Dermatol; 2011 Aug; 36(6):632-4. PubMed ID: 21771009
[TBL] [Abstract][Full Text] [Related]
13. Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis.
Höxtermann S; Nüchel C; Altmeyer P
Dermatology; 1998; 196(2):223-30. PubMed ID: 9568412
[TBL] [Abstract][Full Text] [Related]
14. Fumaric acid esters in combination with a 6-week course of narrowband ultraviolet B provides an accelerated response compared with fumaric acid esters monotherapy in patients with moderate-to-severe plaque psoriasis: a randomized prospective clinical study.
Tzaneva S; Geroldinger A; Trattner H; Tanew A
Br J Dermatol; 2018 Mar; 178(3):682-688. PubMed ID: 29114862
[TBL] [Abstract][Full Text] [Related]
15. Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases.
Harries MJ; Chalmers RJ; Griffiths CE
Br J Dermatol; 2005 Sep; 153(3):549-51. PubMed ID: 16120141
[TBL] [Abstract][Full Text] [Related]
16. Fumaric acid esters for the treatment of psoriasis in Germany: characterising patients in routine care.
Mrowietz U; Sorbe C; Reich K; Von Kiedrowski R; Weckbecker J; Radtke MA; Rustenbach SJ; Augustin M
Eur J Dermatol; 2020 Feb; 30(1):41-48. PubMed ID: 32250255
[TBL] [Abstract][Full Text] [Related]
17. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study.
Mrowietz U; Christophers E; Altmeyer P
Br J Dermatol; 1998 Mar; 138(3):456-60. PubMed ID: 9580799
[TBL] [Abstract][Full Text] [Related]
18. Use of fumaric acid esters in psoriasis.
Roll A; Reich K; Boer A
Indian J Dermatol Venereol Leprol; 2007; 73(2):133-7. PubMed ID: 17456929
[TBL] [Abstract][Full Text] [Related]
19. Immunological changes in psoriasis patients under long-term treatment with fumaric acid esters: risk of Kaposi sarcoma occurrence?
Philipp S; Kokolakis G; Hund M; Witte E; Witte K; Kunz S; Roewert HJ; Sterry W; Sabat R
Eur J Dermatol; 2013; 23(3):339-43. PubMed ID: 23774790
[TBL] [Abstract][Full Text] [Related]
20. Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris.
Gollnick H; Altmeyer P; Kaufmann R; Ring J; Christophers E; Pavel S; Ziegler J
Dermatology; 2002; 205(1):46-53. PubMed ID: 12145434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
